{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:40:42Z","timestamp":1784043642115,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR001453"],"award-info":[{"award-number":["UL1TR001453"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008523","name":"Center for Clinical and Translational Science, University of Illinois at Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008523","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011353","name":"Center for Clinical and Translational Science, University of Massachusetts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.leukres.2023.107388","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T22:00:17Z","timestamp":1694642417000},"page":"107388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations"],"prefix":"10.1016","volume":"134","author":[{"given":"Shyam A.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Wilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayanan","family":"Sadagopan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2023.107388_bib1","series-title":"Leuk Lymphoma","article-title":"Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7\u2009+\u20093","author":"Patel","year":"2023"},{"key":"10.1016\/j.leukres.2023.107388_bib2","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1084\/jem.193.7.855","article-title":"Cd47-signal regulatory protein \u03b1 (Sirp\u03b1) Regulates Fc\u03b3 and complement receptor\u2013mediated phagocytosis","volume":"193","author":"Oldenborg","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.leukres.2023.107388_bib3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRPalpha axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2023.107388_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2023.107388_bib5","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2023.107388_bib6","article-title":"Pre-clinical development of a humanized Anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2023.107388_bib7","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1002\/jcp.30163","article-title":"Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells","volume":"236","author":"Wang","year":"2021","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.leukres.2023.107388_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.leukres.2023.107388_bib9","article-title":"Initial phase 1 results of the first-in-class anti-CD47 antibody Hu5F9-G4 in relapsed\/refractory acute myeloid leukemia patient","author":"Vyas","year":"2018","journal-title":"Eur. Hematol. Assoc. Annu. Meet."},{"issue":"15_suppl","key":"10.1016\/j.leukres.2023.107388_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.7009","article-title":"The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: initial phase 1b results","volume":"37","author":"Sallman","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2023.107388_bib11","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1182\/blood-2018-99-120170","article-title":"Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia","volume":"132","author":"Feng","year":"2018","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.leukres.2023.107388_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.7507","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: phase Ib results","volume":"38","author":"Sallman","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.leukres.2023.107388_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7020","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: phase 1b results","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107388_bib14","unstructured":"Butturini A., Gale R.P. The role of T-cells in preventing relapse in chronic myelogenous leukemia. Bone Marrow Transpl. 987; 2, 351\u2013354."},{"key":"10.1016\/j.leukres.2023.107388_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells","volume":"22","author":"Goncalves Silva","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.leukres.2023.107388_bib16","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood-2004-01-0064","article-title":"In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis","volume":"104","author":"Saudemont","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib17","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib18","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2023.107388_bib19","first-page":"11","article-title":"PD-L1 is expressed and promotes the expansion of regulatory T cells in acute myeloid leukemia","volume":"2020","author":"Dong","year":"1710","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2023.107388_bib20","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"Berger","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.leukres.2023.107388_bib21","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1158\/1078-0432.CCR-17-3763","article-title":"A multi-center phase I trial of ipilimumab in patients with myelodysplastic syndromes following hypomethylating agent failure","volume":"24","author":"Zeidan","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2023.107388_bib22","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"Orskov","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2023.107388_bib23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107388_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26043","article-title":"A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia","volume":"96","author":"Zheng","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"Supplement_1","key":"10.1016\/j.leukres.2023.107388_bib25","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127345","article-title":"Multi-center phase 2 study of pembroluzimab (Pembro) and Azacitidine (AZA) in patients with relapsed\/refractory acute myeloid leukemia (AML) and in newly diagnosed (\u226565 years) AML patients","volume":"134","author":"Gojo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to Azacitidine and Nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.leukres.2023.107388_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.leukres.2023.107388_bib28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.leukres.2023.107388_bib29","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2023.107388_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood-2021-146039","article-title":"Efficacy and Safety of Sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study","volume":"138","author":"Brunner","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib31","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107388_bib32","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.leukres.2023.107388_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0553-5","article-title":"CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2023.107388_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1282","article-title":"Mutated GM-CSF-based CAR-T cells targeting CD116\/CD131 complexes exhibit enhanced anti-tumor effects against acute myeloid leukaemia","volume":"10","author":"Hasegawa","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.leukres.2023.107388_bib35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2014.112748","article-title":"Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia","volume":"100","author":"O\u2019Hear","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107388_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/683065","article-title":"In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia","volume":"2012","author":"Dutour","year":"2012","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.leukres.2023.107388_bib37","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/leu.2014.62","article-title":"Chimeric antigen receptors against CD33\/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo","volume":"28","author":"Pizzitola","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107388_bib38","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41375-018-0075-3","article-title":"Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia","volume":"32","author":"Petrov","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107388_bib39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2017.241","article-title":"CD33-specific chimeric antigen receptor T cells with different co-stimulators showed potent anti-leukemia efficacy and different phenotype","volume":"29","author":"Li","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.leukres.2023.107388_bib40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2023.107388_bib41","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.leukres.2023.107388_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.leukres.2023.107388_bib43","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib44","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1073\/pnas.091097198","article-title":"Surface expression and function of p75\/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells","volume":"98","author":"Vitale","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.leukres.2023.107388_bib45","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2023.107388_bib46","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2023.107388_bib47","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107388_bib48","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/leu.2012.341","article-title":"T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33\/CD3-bispecific BiTE antibody construct","volume":"27","author":"Aigner","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107388_bib49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2013-09-527044","article-title":"Cellular determinants for preclinical activity of a novel CD33\/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML","volume":"123","author":"Laszlo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib50","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","article-title":"CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell\u2013engaging antibody AMG 330","volume":"123","author":"Krupka","year":"2014","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2023.107388_bib51","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood-2018-99-109762","article-title":"A phase 1 first-in-human study of AMG 330, an anti-CD33 bispecific T-Cell engager (BiTE\u00ae) antibody construct, in relapsed\/refractory acute myeloid leukemia (R\/R AML)","volume":"132","author":"Ravandi","year":"2018","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2023.107388_bib52","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2018-99-111529","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2x2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"132","author":"Westervelt","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106178","article-title":"Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia","volume":"84","author":"Hutmacher","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2023.107388_bib54","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/14712598.2019.1623200","article-title":"MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis","volume":"19","author":"van Loo","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.leukres.2023.107388_bib55","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-19-1093","article-title":"Characterization of a novel FLT3 BiTE molecule for the treatment of acute myeloid leukemia","volume":"19","author":"Brauchle","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.leukres.2023.107388_bib56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-022-00660-2","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia","volume":"12","author":"Albinger","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2023.107388_bib57","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/blood-2014-05-575704","article-title":"Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform","volume":"127","author":"Al-Hussaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib58","article-title":"CD47 as a promising therapeutic target in oncology","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.leukres.2023.107388_bib59","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/1078-0432.CCR-16-1700","article-title":"TTI-621 (SIRPalphaFc): A CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding","volume":"23","author":"Petrova","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.leukres.2023.107388_bib60","doi-asserted-by":"crossref","unstructured":"Lin G., Zhang Y., Yu L., Wu D. Cytotoxic effect of CLL\u20111 CAR\u2011T cell immunotherapy with PD\u20111 silencing on relapsed\/refractory acute myeloid leukemia. Mol Med Rep. 202; 23:208.","DOI":"10.3892\/mmr.2021.11847"},{"key":"10.1016\/j.leukres.2023.107388_bib61","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/leu.2015.52","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"Kenderian","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107388_bib62","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly switchable universal CAR-T cells for treatment of CD123-positive leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2023.107388_bib63","first-page":"1359","article-title":"Treating relapsed\/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib64","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","article-title":"Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2023.107388_bib65","doi-asserted-by":"crossref","first-page":"8837","DOI":"10.1182\/blood-2022-169811","article-title":"Filipovic A. Lyt-200, a humanized anti-galectin-9 antibody, exhibits preclinical efficacy in models of hematological malignancies","volume":"140","author":"Henry","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107388_bib66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/10428194.2021.1966779","article-title":"Niche-directed therapy in acute myeloid leukemia: optimization of stem cell competition for niche occupancy","volume":"63","author":"Patel","year":"2022","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212623006537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:04:27Z","timestamp":1758935067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212623006537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":66,"alternative-id":["S0145212623006537"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107388","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107388","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107388"}}